Radiation-Induced Myelosuppression Treatment Market - Key Research Findings
- Global radiation-induced myelosuppression treatment market size in 2018 – nearly US$ 2,500 Mn.
- The radiation-induced myelosuppression treatment market is expected to grow at an approximate CAGR of 3.4% over 2018-2028.
- North America is expected to remain a prominent regional market for radiation-induced myelosuppression treatment
- North America’s position in the radiation-induced myelosuppression treatment market can be attributed to an increase in the number of patients suffering from myelosuppression
- New drug approvals and launches are expected to help companies exploit the growth prospects of the radiation-induced myelosuppression treatment market
- Manufacturers in the radiation-induced myelosuppression treatment market are focusing on getting approvals and launching various biologics as well as small molecules. The recent patent expiry of various biologics has offered the opportunity for manufacturers to launch new biosimilars.
- For example, in May 2018, FDA approved Pfizer’s first erythropoiesis-stimulating agent (ESA) biosimilars for biologics launch by Amgen Inc. (Epogen) and Procrit launched by Janssen Pharmaceutical NV
- In June 2018, FDA approved the first biosimilar Fulphila manufactured by Mylan N.V. to Amgen Inc.’s Neulasta (Pegfilgrastim) biologics.
Top 2 Factors Shaping the Global Radiation Induced Myelosuppression Treatment Market
The Availability of Drugs for the Treatment of Anemia and Thrombocytopenia
The management of neutropenia has become easier with the availability of various growth factors as well as that of desired treatment guidelines for their management. However, anemia and thrombocytopenia remain among the major clinical problems. Although thrombocytopenia is effectively managed with the help of the available growth factors, most of them are off-label.
The management of anemia remains one of the high unmet needs among cancer patients who receive radiation therapy for cancer treatment. Due to changes in the reimbursement and labelling of anemia-associated drugs in 2007, the off-label indication use of erythropoietin-stimulating agents has decreased drastically owing to a reduction in their usage in anemia management.
The above changes have increased the need for blood transfusion, which is associated with various risk factors. Hence, the prevalence of radiotherapy-induced anemia offers a vast opportunity for revenue generation.
Increasing Use of ESA Along with Iron Supplements
Various studies pertaining to the off-label use of Erythropoiesis-Stimulating Agents (ESA) for the treatment of radiation induced anemia are being carried out. Moreover, due to a decrease in the use of ESA, various studies are focused on evaluating the response of ESA to anemia.
The response rate of ESA alone in patients suffering from radiation-induced anemia is reported in between 62 and 73%, whereas the response of ESA when used along with iron supplements such as Feritin increased up to 72% – 86% (Auerbach et al.). By using ESA and iron therapy together, the need for blood transfusion in case of radiation-induced anemia has decreased substantially.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Radiation-Induced Myelosuppression Treatment Market Structure Analysis
- The global radiation induced myelosuppression treatment market represents a consolidated competition landscape, wherein the major companies hold three-fourth of the revenue share
- Most of the manufacturers in the radiation-induced myelosuppression treatment market are focusing on the North America and Europe regions
- Manufacturers are focusing on strategic expansion through acquisitions & mergers with other companies around the world, and ensuring the availability of their products by strengthening their manufacturing facilities
- The company also focuses on building a value chain to develop new products and sustainable solutions, as well as to optimize the generics portfolio to match demands with greater focus on profitability
- Some of the prominent companies in the radiation-induced myelosuppression treatment market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Amgen Inc., Janssen Global Services, LLC (Johnson & Johnson), Partner Therapeutics, Inc., Mission Pharmacal Company, Myelo Therapeutics GmbH, and Pluristem Therapeutics Inc.
Radiation-Induced Myelosuppression Treatment – Increasing Incidence of Cancer
Growing incidence of cancer worldwide and decreased death rate owing to early diagnosis and the availability of innovative treatment options such as radiotherapy and chemotherapy are among factors expected to fuel the growth of the radiation-induced myelosuppression treatment market.
In addition, the increasing adoption of adjuvant therapy for cancer, i.e., along with radiotherapy, has a significant impact on the declining death rate as well as the management of cancer, along with the quality of life in patients suffering from cancer.
Market is set to Grow Over 1.4X between 2018 and 2028
The radiation-induced myelosuppression treatment market is likely to witness moderate growth over the forecast period, which is expected to be driven by the increasing usage of radiotherapy devices for cancer treatment, as well as the increasing usage of ESA along with iron supplements.
Furthermore, the use of radiation in cancer treatment is increasing due to its site-specific nature, which is among the most important factors for the early diagnosis of cancer patients. This is another factor that is expected to propel the radiation-induced myelosuppression treatment market.
Stakeholders Aiming at Tapping the Potential of Emerging Markets
There are several opportunities for the growth of the radiation-induced myelosuppression treatment market across emerging economies such as China, India, and GCC countries. The company operating in the market are continuously making efforts to sustain future growth through the expansion of indications for their already approved drugs.
Companies are expanding their presence in developing regions such as Latin America and Asia Pacific.
The Broader Perspective
The radiation-induced myelosuppression treatment market continues to witness growth as companies focus on the launch and approval of biosimilars due to the patent expiry of various drugs. Increase in research and development to increase the ease of managing cancer therapy-associated adverse effects is expected to further fuel the radiation-induced myelosuppression treatment market.
How Growth will Unfold
ESA are expected to account for the second most lucrative segment in the radiation-induced myelosuppression treatment market by drug type owing to the improved efficacy of iron therapy with ESA. IV iron therapy, along with ESA, helps bring back the RBC count to normal as compared to the treatment of ESA alone.
This significant change in the response rate is expected to help improve the efficacy and therapeutic outcome, as well as patient compliance. These factors are estimated to boost the demand for ESA in the radiation-induced myelosuppression treatment market.
The global radiation-induced myelosuppression treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.
Based on indication
Based on drug class
- growth factors
- erythropoietin stimulating agents
- thrombopoietic agents
- iron supplements
Based on route of administration
Based on distribution channel
- hospitals pharmacies
- retail pharmacies
- online pharmacies
- drug stores
Based on regions
- North America
- Latin America
- Eastern Europe
- Western Europe
- Asia-Pacific excluding Japan
- Middle East & Africa